Skip to main content
Top
Published in: International Urology and Nephrology 8/2021

01-08-2021 | Echocardiography | Nephrology - Original Paper

Association of fetuin-A levels and left ventricular diastolic dysfunction in patients on haemodialysis

Authors: Yangang Gan, Mingming Zhao, Jinhong Feng

Published in: International Urology and Nephrology | Issue 8/2021

Login to get access

Abstract

Objective

To identify the relationship between serum fetuin-A levels and left ventricular diastolic dysfunction (LVDD) among maintenance haemodialysis patients.

Methods

In a cross-sectional study, 75 dialysis patients with end-stage renal disease (ESRD) were recruited, and fetuin-A levels were detected using an enzyme-linked immunosorbent assay (ELISA). Echocardiography measurements were recorded according to the recommendations of the American Society of Echocardiography. The ratio of early diastolic transmitral inflow velocity (E) to early diastolic annular velocity (E′) was measured using tissue Doppler imaging and E/E′ > 15 was defined as diastolic dysfunction. The association of serum fetuin-A concentrations with echocardiographic parameters was analysed by calculating the bivariate linear correlation. A binary logistic regression analysis was conducted to determine the variables associated with LVDD.

Results

Compared to patients without diastolic dysfunction, patients with diastolic dysfunction were older, a higher percentage had a history of coronary artery disease, and presented with a high systolic pressure, high parathyroid hormone level, high N-terminal pro-brain natriuretic peptide (NT-proBNP) level, high LV mass index, high left atrium diameter, and low serum creatinine and fetuin-A levels. Serum fetuin-A levels showed a negative correlation with E/E′ (r = − 0.299, P = 0.009). Fetuin-A levels were considered an independent predictor of diastolic dysfunction.

Conclusion

A decrease in the serum fetuin-A level is associated with an increased risk of LVDD in patients on haemodialysis.
Literature
9.
10.
go back to reference Foley RN, Parfrey PS (1998) Cardiovascular disease and mortality in ESRD. J Nephrol 11:239–245PubMed Foley RN, Parfrey PS (1998) Cardiovascular disease and mortality in ESRD. J Nephrol 11:239–245PubMed
20.
go back to reference Horii M, Matsumoto T, Uemura S, Sugawara Y, Takitsume A, Ueda T, Nakagawa H, Nishida T, Soeda T, Okayama S, Somekawa S, Ishigami K, Takeda Y, Kawata H, Kawakami R, Saito Y (2013) Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function. J Cardiol 61:410–416. https://doi.org/10.1016/j.jjcc.2013.01.015CrossRefPubMed Horii M, Matsumoto T, Uemura S, Sugawara Y, Takitsume A, Ueda T, Nakagawa H, Nishida T, Soeda T, Okayama S, Somekawa S, Ishigami K, Takeda Y, Kawata H, Kawakami R, Saito Y (2013) Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function. J Cardiol 61:410–416. https://​doi.​org/​10.​1016/​j.​jjcc.​2013.​01.​015CrossRefPubMed
Metadata
Title
Association of fetuin-A levels and left ventricular diastolic dysfunction in patients on haemodialysis
Authors
Yangang Gan
Mingming Zhao
Jinhong Feng
Publication date
01-08-2021
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2021
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-021-02796-9

Other articles of this Issue 8/2021

International Urology and Nephrology 8/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.